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Abstract: Panic disorder is a chronic, recurrent illness, with a lifetime prevalence of about
5%. It is associated with substantial functional impairment, and studies suggest that treatment
with medication alone (and no instruction in exposure to feared and avoided situations) is less
than optimal. In fact, 40%–90% of patients in long-term follow-up studies in the late 1980s
and early 1990s, treated with antidepressants or high potency benzodiazepines alone, remained
somewhat symptomatic. Venlafaxine extended release (XR) was effective and well tolerated
in both the short-term and long-term treatment of panic disorder. In 12-week trials, venlafaxine
XR was significantly more effective than placebo in achieving a panic-free state (54%–70%
vs 34%–48%, p≤0.05), and was as effective as paroxetine. In addition, venlafaxine XR has
been shown to produce significantly higher response and remission rates than placebo. Relapse
rates were significantly reduced with ongoing venlafaxine XR treatment compared to switching
to placebo (22% vs 50%, p≤0.001), in a 6 month study. Importantly, venlafaxine XR
significantly improved patient quality of life and functioning, and was generally well tolerated.
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Introduction
Panic disorder is a prevalent psychiatric disorder, which can significantly impact an
individual’s emotional and functional wellbeing (Sherbourne et al 1996; Roy-Byrne
et al 2000; Ramage-Morin 2004; Kessler, Berglund, et al 2005; Kessler, Chiu, et al
2005). Treatment for panic disorder most often involves antidepressants, however,
only about half of patients will become panic free on antidepressants alone (Otto et
al 2001; Bakker et al 2002). In addition, follow-up studies of patients with panic
disorder at 1 to 5 years after initiation of antidepressants or high potency
benzodiazepines demonstrate that 40%–90% of patients remain at least somewhat
symptomatic (Noyes et al 1989; Nagy et al 1989, 1993). Clearly, there remains room
for improvement in the treatment of panic disorder.
Cognitive behavioural therapy (CBT) is the other mainstay in the treatment of
panic disorder. Some form of exposure (individual or group CBT or self-help books)
is essential to furthering the treatment response beyond cessation of panic attacks.
Exposure helps to eliminate the anticipatory anxiety and agoraphobic avoidance,
which are the most functionally disabling aspects of panic disorder with agoraphobia.
Efficacy, safety, and tolerability of venlafaxine extended release (XR) has been
established for depression (Smith et al 2002), generalized anxiety disorder (Gelenberg
et al 2000), and social anxiety disorder (Allgulander et al 2004). Recently, venlafaxine
XR has been approved for use in the treatment of panic disorder in a number of
countries. This paper will review the current evidence for clinical efficacy, safety,
tolerability, and quality of life improvements with venlafaxine XR in the short and
long-term treatment of panic disorder.
Diagnosis of panic disorder
The diagnostic and statistical manual of mental disorders, text revised (DSM-IV-
TR), criteria for the diagnosis of panic disorder are shown in Table 1 (APA 2000).
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Panic disorder may be associated with agoraphobia, defined
as anxiety about being in places or situations from which
escape might be difficult or embarrassing, or in which help
may not be available in the event of having an unexpected
or situationally-predisposed panic attack or panic-like
symptoms (APA 2000).
Burden of panic disorder
Prevalence
Panic disorder is a chronic, recurrent illness associated with
substantial functional impairment and cost to the individual
and society. Panic attacks have an estimated lifetime
prevalence of 15% (Eaton et al 1994).However, the
diagnosis of panic disorder is less common, with a lifetime
prevalence of 4.7% (Kessler, Berglund, et al 2005; Kessler,
Chiu, et al 2005). Therefore, many individuals with a history
of panic attacks do not have panic disorder. Approximately
30% of the population will suffer at least one panic attack
in any one year, without having any formal psychiatric
disorder (Norton et al 1985).
Panic attacks are often seen in mood and anxiety
disorders, but also in patients with schizophrenia and
borderline personality disorder. Thirty percent of patients
with unipolar depression and 60% of patients with bipolar
depression,including mixed states, will have panic attacks
as part of their mood disorder (Angst 1996). Prepubertal
onset of panic attacks and treatment refractory panic attacks
should increase suspicion of bipolar disorder. (Mackinnon
et al 2002).
Approximately one-third to one-half of patients with
panic disorder have symptoms of agoraphobia (Eaton et al
1994). Panic disorder and agoraphobia are more common
in women than men (Eaton et al 1994; Weissman et al 1997).
The onset of panic disorder usually occurs in late
adolescence or early adulthood (Kessler, Berglund, et al
2005; Ramage-Morin 2004). For patients who present with
anxiety symptoms, including panic attacks, for the very first
time after the age of 45, the most likely primary diagnosis
is depression.
Impact
Panic disorder can have a profound impact on an individual’s
quality of life. Individuals with panic disorder are less likely
to work and more likely to be permanently unable to work,
compared with those who have never had the disorder
(Sherbourne et al 1996; Roy-Byrne et al 2000; Ramage-
Morin 2004). Patients with panic disorder have greater
impairment in functioning than patients with diabetes, heart
disease, or arthritis (Sherbourne et al 1996).
Approximately 80% of panic disorder patients
experience other co-morbid psychiatric conditions. (Kessler,
Berglund, et al 2005). Comorbid depression is particularly
common and has a negative impact on outcomes including
an increased risk of suicide (Fawcett 1997; Coryell et al
1988; Weissman et al 1999; Roy-Byrne et al 2000; Goodwin
et al 2001).
Comorbid medical conditions should also be considered
in patients with panic disorder, including respiratory diseases
such as asthma (Goodwin et al 2003; Zandbergen et al 1991),
vestibular dysfunction (Staab et al 2002), and thyroid disease
(hypothyroidism and hyperthyroidism) (Simon et al 2002).
Chest pain and palpitations are frequent symptoms of panic
attacks and may be difficult to differentiate from cardiac
disease. While 43% of patients presenting to the emergency
department with atypical chest pain have been found to have
panic attacks or panic disorder (Wulsin et al 1988), the
presence of panic disorder does not preclude coronary artery
disease (CAD). Anxiety has been shown to increase the risk
of CAD and cardiac death (Kawachi, Colditz, et al 1994;
Kawachi, Sparrow, et al 1994; Albert et al 2005). The cause
Table 1 DSM-IV-TR diagnosis of panic disorder (with or without agoraphobia). Reprinted with permission from the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Copyright © 2000. American Psychiatric Association.
• The person has experienced both of the following: 
• recurrent unexpected panic attackse
• ≥1 of the attacks has been followed by ≥1 month of ≥1 of the following:
• persistent concern about having additional attacks
• worry about the implications of the attack or its consequences 
• a significant change in behavior related to the attacks
• The presence (or absence) of agoraphobia
• The panic attacks are not due to substance abuse, a medication, or a general medical condition
• The panic attacks are not better accounted for by another mental disorder Therapeutics and Clinical Risk Management 2007:3(1) 61
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of this increased risk is likely multifactorial. Possibilities
include decreased heart rate variability (Tucker et al 1997;
Yeragani et al 2000; Sullivan et al 2004) and increased pro-
inflammatory cytokines and cortisol, which are associated
with stress diathesis disorders. Additionally, smoking,
another risk factor for CAD, is common among panic
disorder patients.
Overview of pharmacological
treatment of panic disorder
Pharmacologic treatment, often in combination with
cognitive-behavioral therapies, can be tailored for the
individual patient based on specific anxiety symptoms,
comorbid disorders, and history of side effects (Roy-Byrne
et al 1993).
Pharmacotherapeutic interventions that have
demonstrated efficacy in treating panic disorder include
selective serotonin reuptake inhibitors (SSRIs), the serotonin
and norepinephrine reuptake inhibitor (SNRI) venlafaxine
XR, tricyclic antidepressants (TCAs), and benzodiazepines.
Current published guidelines from Canada, the United
Kingdom, Singapore, and Australia and New Zealand
generally recommend antidepressants as first line therapy
for the treatment of panic disorder (Bandelow et al 2002;
Ministry of Health 2003; Royal Australian and New Zealand
College of Psychiatrists 2003; Mcintosh et al 2004; Canadian
Journal of Psychiatry Clinical Practice Guidelines 2006).
SSRIs and TCAs have demonstrated equivalent efficacy,
but most guidelines suggest that TCAs are less well tolerated.
Generally, antidepressants are preferred over
benzodiazepines as first line treatment because, unlike
benzodiazepines, antidepressants treat comorbid depression
without risk of dependency and the potential for side effects
such as excessive sedation, cognitive impairment, and ataxia.
Individuals with panic disorder may have increased
sensitivity to medication side effects such as tachycardia,
dizziness, dry mouth, and tremor. These side effects are
sometimes incorrectly attributed to medical disorders (Roy-
Byrne et al 1993). Anxiety about physical symptoms may
increase at the onset of antidepressant treatment; therefore,
it is important to start with low doses and educate patients
about possible adverse events to reduce distress and prevent
nonadherence with treatment.
Defining remission in panic disorder
The concept of remission and the impact of failing to acheive
remission is not as well established in anxiety disorders as
in depression (Frank et al 1991; Paykel 1998). However, it
is likely that achieving remission in anxiety disorders has a
similar positive relationship to outcome as is seen in
depression (Ballenger 2001). A number of assessment tools
have been designed to quantify the severity of panic
symptoms, response to therapy, and functional impairment
(Table 2) (Liebowitz et al 2004).
The goals of therapy are to decrease the frequency and
severity of panic attacks, as well as to reduce anticipatory
Table 2 Description of Panic Disorder Assessment Scales Reprinted with permission from Liebowitz M, Asnis G, Tzanis E, et al.
2004.  Venlafaxine extended release versus placebo in the short-term treatment of panic disorders. New Research Abstracts from
the APA Annual Meeting. Copyright © 2004. American Psychiatric Association.
Scale Description
Panic and Anticipatory Measures the frequency, average duration, average intensity, and type of attack (full- or limited-symptom and
Anxiety Scale (PAAS) expected or unexpected), percentage of time awake spent having anticipatory anxiety and the intensity of the
anticipatory anxiety.
Panic Disorder Severity A 7-item clinical interview assessment instrument designed to measure the severity of panic disorder symptoms. It
Scale (PDSS) rates core features of panic disorder, including frequency of full symptom and limited-symptom panic attacks,
distress caused by panic attacks, anticipatory anxiety, agoraphobic fear/avoidance, panic related sensation fear/
avoidance, and work and social impairment.
Phobia Scale Evaluates the extent of fear and the avoidance of things or situations that patients fear (if any).
Sheehan Disability Scale Includes 3 specific domains that capture key aspects of patient disability (work, social life/ leisure, family life/home
responsibilities). Responses on these 3 domains are scored on an 11-point (0 to 10) discrete analog scale with
higher scores representing greater impairment (0=not at all impaired; 10=very severely impaired). Also includes a 5-
point work and social disability scale (1=normal activity; 5=symptoms prevent normal work or social activities).
Quality of Life Enjoyment Includes domains that measure physical health/activities, subjective feelings of well-being, work, household duties,
and Satisfaction school/ coursework, leisure time, social relations, general well-being, satisfaction with medication, and overall life
Questionnaire  satisfaction.  Responses are measured on a 5-point Likert scale with higher scores indicating better functioning.Therapeutics and Clinical Risk Management 2007:3(1) 62
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anxiety, fear-driven avoidance, and impairment in
functioning associated with panic disorder (Table 3)
(Ballenger 2001; Royal Australian and New Zealand College
of Psychiatrists 2003). Suggested criteria for remission of
panic disorder are outlined in Table 3 (Ballenger 2001).
Patients were considered to have remitted in the placebo-
controlled trials outlined in this paper when their Clinical
Global Impression – Improvement (CGI-I) =1 and they were
panic free.
Clinical efficacy of venlafaxine XR
for panic disorder
Venlafaxine XR, a structurally novel phenylethylamine
antidepressant, has a dual mechanism of action, acting as
both a serotonin and norepinephrine reuptake inhibitor
(SNRI), with little or no affinity for muscarinic,
histaminergic or adrenergic receptors (Muth et al 1986).
Potentiation of neurotransmission involves a tonic increase
in serotonin and norepinephrine in synaptic clefts throughout
the central nervous system. Through norepinephrine
reuptake inhibition,which increases exponentially at doses
above 150 mg, venlafaxine attenuates phasic noradrenergic
reactivity (Morilak and Frazer 2004; Blier and Szabo 2005.
This is the noradrenergic neuronal firing in response to
stressful or threatening stimuli (Cecchi et al 2002; Pardon
et al 2002). When there is an increase in extracellular
norepinephrine, one would expect a desensitization of alpha-
2 autoreceptors on the cell body. This does not occur
however. If they were desensitized, neuronal firing would
increase.This attenuation of noradrenergic neuronal firing
could contribute to the anxiolytic effect of venlafaxine.
An early, small, proof-of-concept study in 25 patients,
indicating that venlafaxine might be efficacious in panic
disorder (Pollack et al 1996), formed the basis of further
investigations. Four large, randomized controlled trials are
available, demonstrating the robust efficacy of venlafaxine
for the short-term (Liebowitz et al 2004; Pollack et al 2004,
2005; Bradwejn et al 2005) and long-term (Ferguson et al
2005) treatment of panic disorder (Table 4). There are also
data indicating that venlafaxine offers improved quality of
life for patients with panic disorder (Khandker et al 2005).
Placebo-controlled trials
A multicenter, randomized, placebo-controlled trial
evaluated the safety and efficacy of venlafaxine XR in 328
adults with panic disorder, with or without agoraphobia, of
at least 6 months duration (Bradwejn et al 2005). Patients
were randomized to either flexible-dose venlafaxine XR
(75 mg/day to 225 mg/day; mean daily dose 115–163 mg)
or placebo for 10 weeks. Treatment with venlafaxine resulted
in statistically significant improvement compared with
placebo in terms of the percentage of patients free from full-
symptom panic attacks (the primary outcome measure), at
weeks 4 and 8, but not at the final evaluation, (55.0% vs
52.4%, respectively; p=nonsignificant) (Table 4) (Bradwejn
et al 2005).
However, response (defined as CGI-I ≤2; Figure 1) and
remission rates (defined as CGI-I=1 and panic-free; Figure
2) were significantly higher with venlafaxine XR at
endpoint. Other secondary outcome measures, including
improvements in the fear and avoidance factors of the Phobia
Scale, and in quality of life, were also significantly greater
with venlafaxine XR (Bradwejn et al 2005).
Another 10-week, multicenter, placebo-controlled trial
randomized 310 patients to either flexible dose venlafaxine
XR (75 mg/day to 225 mg/day; mean daily dose 125.6–
194.1 mg) or placebo (Liebowitz et al 2004). The only
significant difference in baseline characteristics between the
groups was a higher percentage of women in the venlafaxine
XR group (72% vs 59% in the placebo group, p=0.031).
Table 3 Remission of panic disorder. Adapted with permission from Ballenger J. 2001. Treatment of anxiety disorders to remission.
J Clin Psychiatry, 62(Suppl 12):5-9. Copyright © 2001. Physicians Postgraduate Press.
Option 1 Option 2
• Essentially free of panic attacks • PDSS total score ≤3, with no individual item score >1
• No or mild agoraphobic avoidance
• No or minimal anxiety
• HAM-A score ≤7–10
• No functional impairment
• Sheehan Disability Scale score ≤1 (mildly disabled)
• HAM-D score ≤7 • HAM-D score ≤7
Abbreviations: HAM-A, Hamilton Rating Scale for Anxiety; HAM-D, Hamilton Rating Scale for Depression; PDSS, Panic Disorder Severity Scale.Therapeutics and Clinical Risk Management 2007:3(1) 63
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Venlafaxine XR-treated patients showed improvement
in panic frequency as compared to placebo, but this
difference did not achieve statistical significance (panic free:
51.0% vs 40.6%; p=0.056). However, response rates (CGI-
I score 1 or 2), were significantly higher with venlafaxine
XR (71.1%) compared with placebo (58.8%, p=0.031), and
there was a trend toward higher remission rates (CGI-I = 1
and panic-free) with venlafaxine XR (37.5% and 27.%,
p=0.067) (Table 4). Venlafaxine XR-treated patients
demonstrated a significant difference from placebo on the
Panic Disorder Severity Scale (PDSS) (p=0.02), and the
Phobia Scale measures of fear (p=0.007) and avoidance
(p=0.026), as well as significant improvements in quality
of life measures (Liebowitz et al 2004).
Comparative trials
Two multicenter, double blind, 12-week trials, including
over 1200 patients, have assessed the safety and efficacy of
venlafaxine XR compared with paroxetine and placebo for
the treatment of panic disorder (Pollack et al 2004, 2005).
The first trial included 634 patients with panic
disorder,with or without agoraphobia, randomized to one
of four groups: venlafaxine XR 75 mg/day, venlafaxine XR
150 mg/day, paroxetine 40 mg/day or placebo (Pollack et al
2004). There were no significant differences in baseline
characteristics between the groups.
Venlafaxine XR 75 mg or 150 mg, and paroxetine 40 mg
were associated with significant improvements compared
with placebo, and there were no significant differences
between venlafaxine and paroxetine treatment. The
percentages of patients free of panic attacks were: 54% with
venlafaxine XR 75 mg, 61% with venlafaxine XR 150 mg,
60% with paroxetine, and 34% with placebo (p<0.001 for
all active treatments vs placebo) (Table 4). Remission was
achieved by a significant proportion of venlafaxine XR-
treated patients as early as week 4 (venlafaxine 75 mg vs
placebo, p<0.01; venlafaxine 150 mg vs placebo, p<0.05),
and by paroxetine-treated patients as early as week 6 (p<0.05
vs placebo). In general, the incidence and severity of
treatment-emergent adverse events were similar among the
three active treatment groups.
Table 4 Double-blind trials evaluating venlafaxine XR in patients with panic disorder.
Study Treatment Response Rate Remission Rate Panic-free
(n value) mg/day CGI-I 1 or 2 Panic-free and Free of full symptom
Study duration  % CGI-I=1  panic attacks 
%%
Bradwejn 2005 VEN 75–225 mg 68.1 35.6 55
(n=328) (flexible dose)
10 weeks Placebo 55.4 24.4 52.4
(Bradwejn et al 2005) p=0.023 p=0.03 p=0.622
Liebowitz 2004 VEN 75–225 mg 71.1 37.5 51
(n=310) (flexible dose)
10 weeks Placebo 58.8 27.5 40.6
(Liebowitz et al 2004) p=0.031 p=0.067 p=0.056
Pollack 2004 VEN 75 mg 77 45* 54
(n=634) VEN 150 mg 79 47** 61
12 weeks PRX 40 mg 81 46** 60
(Pollack et al 2004) Placebo 56 27 34
p<0.001 (vs placebo) *p=0.001, p<0.001 (vs placebo)
**p<0.001 (vs placebo)
Pollack 2005 Panic-free and CGI-S 1
(n=624) or 2
12 weeks VEN 75 mg 83.2 42* 64.7*
(Pollack et al 2005) VEN 225 mg 88.6 51** 70.0*†
PRX 40 mg 83.8 39*** 58.3**
Placebo 62.3 27 47.8
p<0.001 *p≤0.01, *p<0.001,
(vs placebo) ** p<0.001, **p<0.05 (vs placebo)
***p<0.05 (vs placebo) †p <0.05 (vs paroxetine)
Abbreviations: CGI-I, Clinical Global Impressions – Improvement; CGI-S, Clinical Global Impressions – Severity;  VEN, venlafaxine XR; PRX, paroxetine; XR,
extended release.Therapeutics and Clinical Risk Management 2007:3(1) 64
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The second comparative trial was similar in design and
included 624 adults with panic disorder,with or without
agoraphobia, who were randomized to venlafaxine XR
75 mg/day, venlafaxine XR 225 mg/day, paroxetine 40 mg/
day or placebo (Pollack et al 2005). There were no
significant differences in baseline and demographic
characteristics between the groups.
Treatment with venlafaxine XR 75 mg, venlafaxine XR
225 mg, and paroxetine 40 mg was associated with
significant improvements compared with placebo. The
percentage of patients free of panic attacks was 64.7% with
venlafaxine XR 75 mg, 70.0% with venlafaxine XR 225 mg,
58.3% with paroxetine, and 47.8% with placebo (p<0.001
for both venlafaxine groups vs placebo, p<0.05 for
paroxetine vs placebo) (Table 4) (Pollack et al 2005). The
venlafaxine XR 225 mg group had a statistically significant
higher percentage of panic-free patients (p<0.05) and
significantly greater PDSS score improvement (p<0.05) at
endpoint than paroxetine. Sustained remission (panic-free
and CGI-Sustained [CGI-S] of 1 or 2) was achieved in a
significant proportion of venlafaxine XR-treated patients
by week 6, and in paroxetine-treated patients by week 8.
Response and remission rates were comparable between the
active treatment groups, with over 75% of patients
considered responders, and 39-51% of patients considered
remitters. All 3 active treatment groups showed greater
improvement than the placebo group on the Hamilton Rating
Scale for Anxiety (HAM-A) and the Hamilton Rating Scale
for Depression (HAM-D). The authors concluded that
venlafaxine XR and paroxetine were safe, efficacious, and
well tolerated in the short-term treatment of panic disorder.
Data in adolescents and children
A 10-week, double blind, placebo controlled trial examined
the safety and efficacy of flexible-dose venlafaxine XR in
48 adolescents (aged 12 to 17 years) with panic disorder,with
or without agoraphobia (Albano et al 2006). There were no
significant differences between the venlafaxine XR and
placebo groups at any time point for panic attack frequency,
PDSS total score, or response rates (defined as CGI-I=1 or
2) (Albano et al 2006).Furthermore, there was no evidence
of an increased risk of adverse events in this patient group.
There were no deaths in the study, no indicators of
suicidality, no serious adverse events, and no
discontinuations due to adverse events in the venlafaxine
group. However, physicians should follow patients closely
and be on alert for signs of suicidal ideation in patients taking
venlafaxine XR or any other antidepressant. Starting with
low doses may minimize the risk of increasing anxiety and
panic attacks, which are independent risk factors for
increased suicide attempts in depressed adults (Fawcett
1997).
Long-term efficacy and relapse
prevention
The long-term efficacy and safety of venlafaxine XR has
been examined in a multicenter, randomized, placebo-
controlled trial (Ferguson et al 2005). Patients who were
responders (≤1 full symptom panic attack per week in the
last 2 weeks of open-label treatment and a CGI-I ≤2) to
venlafaxine XR (flexible dose 75–225 mg per day; mean
daily dose 172.1 mg [± 53.2 mg]) in a 12-week, open label
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Figure 1 Response rates with venlafaxine XR and placebo over time. Copyright © 2005. Reprinted with permission from Bradwejn J, Ahokas A, Stein DJ, et al. 2005.
Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry, 187:352-9.
Notes: *p<0.05 vs placebo; **p<0.01 vs placebo; Response defined as CGI-I =1 or 2.
Abbreviations: CGI-I, Clinical Global Impressions – Improvement; XR, extended release.Therapeutics and Clinical Risk Management 2007:3(1) 65
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study, were randomized to continue receiving their open-
label dosage of venlafaxine XR (mean daily dose 164.9mg
per day during the initial 2 week period of the double-blind
phase) or switch to placebo for up to 6 months (venlafaxine
XR=89, placebo n=80). Relapse was defined as having 2 or
more full-symptom panic attacks per week for 2 consecutive
weeks or discontinuing therapy because of loss of
effectiveness. Venlafaxine XR was significantly better than
placebo in preventing relapse in patients who had responded
to open-label treatment. According to the Kaplan-Meier
survival analysis, 22.5% of patients in the venlafaxine XR
group relapsed, compared with 50% of patients in the
placebo group (p<0.001) (Ferguson et al 2005).
Venlafaxine XR demonstrated significant improvement
in most other secondary efficacy variables, including the
percentage of patients who were panic-free on venlafaxine
XR (52.8%) compared to placebo (31.3%) (p=0.005), and
mean panic frequency (p<0.001). There were also significant
improvements in the PDSS, anticipatory, psychic, and
somatic anxiety, and fear and avoidance, as well as CGI-S
and quality of life in the venlafaxine XR group compared
with placebo (Ferguson et al 2005). Venlafaxine XR-treated
patients were significantly less likely to withdraw from the
study for any reason, than were patients treated with placebo
(p<0.001).
Improved quality of life
Panic disorder is characterized by substantial impairment
in patient-reported quality of life attributable to both
emotional and physical health (Katerndahl and Realini
1997). The National Institutes of Health Consensus
Development Conference on the Treatment of Panic
Disorder has recommended that measures of patient-
reported quality of life and functioning are essential and
should be included in clinical studies in panic disorder
(Shear and Maser 1994).
In placebo-controlled short term trials, venlafaxine XR
improved 3 out of 4 Sheehan Disability Scale (SDS)
domains, and most of the domains assessed with the Quality
of Life Enjoyment and Satisfaction Questionnaire (Q-LES-
Q) (Liebowitz et al 2004; Bradwejn et al 2005). In the long-
term trial, venlafaxine XR was significantly better than
placebo in improving SDS work, social life and leisure
activities, family life and home responsibilities, and global
work and social disability scores over 6 months of treatment
(p<0.001) (Ferguson et al 2005). Venlafaxine XR-treated
patients also showed significantly greater improvement from
baseline on all but 1 of the 10 Q-LES-Q subscales (school/
course work) compared with placebo at 6 months (Ferguson
et al 2005).
The two 12-week, multicenter studies comparing
venlafaxine with paroxetine and placebo included secondary
analyses of functional impairment (SDS) and quality of life
(Q-LES-Q) (Zhang et al 2004; Khandker et al 2005). At
baseline, patients were most impaired on the Q-LES-Q
subscales relating to school/course work, overall life
satisfaction, satisfaction with medication, and physical
health and activities (Zhang et al 2004; Khandker et al 2005).
At study end, venlafaxine XR was associated with
improvements in 7 to 9 of the 10 subscales of the Q-LES-
Q, and paroxetine with improvements in 7 to 10 of the 10
subscales (Zhang et al 2004; Khandker et al 2005). In
Figure 2 Remission rates with venlafaxine XR and placebo over time. Copyright © 2005. Reprinted with permission from Bradwejn J, Ahokas A, Stein DJ, et al. 2005.
Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry, 187:352-9.
Note: *p<0.05 vs placebo, **p<0.01 vs placebo; Remission defined as panic-free (PASS) and CGI-I=1; ITT, population; LOCF, last observation carried forward; FOT,
final on-therapy evaluation.
Abbreviations: CGI-I, Clinical Global Impressions – Improvement; ITT, intent-to-treat; XR, extended release.
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general, school/course work and household duties subscales
were more resistant to improvement with treatment. Both
the 75 mg and 225 mg doses of venlafaxine XR, as well as
paroxetine, were superior to placebo on all 4 SDS subscales
(p<0.01) (Khandker et al 2005).
Predictors of response to venlafaxine
A pooled analysis of the four major clinical trials, including
a total of 1595 adults with panic disorder, evaluated
predictors of clinical outcomes in the short-term treatment
of panic disorder (Pollack et al 2006). Greater mean
symptom severity and female gender were associated with
lower proportions of panic-free patients, in both the
venlafaxine XR and the placebo treated group. Among
patients treated with venlafaxine XR, 69% of those classified
as low severity at baseline were panic free at endpoint
compared with 51% of patients in the high severity group
(p<0.05). Similarly, 65% of men achieved panic-free status
compared with 57% of women (p<0.05). For those treated
with placebo, significantly more patients in the low severity
group (53%), compared with the high severity group (32%),
and men (50%) compared with women (40%), were panic-
free at endpoint.
Safety and tolerability of
venlafaxine XR in panic disorder
In general, the incidence and severity of treatment-emergent
adverse events observed with venlafaxine XR in panic
disorder were similar to those observed in studies for
depression, generalized anxiety disorder, and social anxiety
disorder (Pollack and Whitaker 2003; Liebowitz et al 2004;
Bradwejn et al 2005; Ferguson et al 2005; Pollack et al 2005;
Albano et al 2006).
In placebo-controlled trials, the most common treatment-
emergent adverse events reported by at least 5% of patients
in the venlafaxine XR group, and at least twice the rate of
placebo, were: insomnia, dry mouth, sweating, abnormal
ejaculation/orgasm, constipation, decreased libido,
somnolence, anorexia, palpitations, vasodilatation,
hypertension, nausea, accidental injury, and impotence
(Liebowitz et al 2004; Bradwejn et al 2005; Ferguson et al
2005). In these trials, treatment discontinuation due to
adverse events were reported in 1%–9% of venlafaxine-
treated patients compared with 2%–4% in the placebo group
(Liebowitz et al 2004; Bradwejn et al 2005; Ferguson et al
2005).
In comparative trials with paroxetine, adverse events
were similar in both active treatment groups (Pollack and
Whitaker 2003; Pollack et al 2005). Discontinuations due
to adverse events were similar between the groups in
comparative trials: 2%–8% in the venlafaxine XR 75 mg
group, 12% in the venlafaxine XR 150 mg group, <1% in
the venlafaxine XR 225 mg group, 5%–10% in the
paroxetine 40 mg group, and 2%–9% in the placebo group
(Pollack and Whitaker 2003; Pollack et al 2005).
In the long-term trial, venlafaxine XR-treated patients
were significantly less likely to withdraw from the study
for any reason compared with patients treated with placebo
(p<0.001) (Ferguson et al 2005).
Potential drug interactions
Venlafaxine is metabolized by the cytochrome P450
isoenzyme 2D6 and therefore its metabolism is modified
by medications that inhibit or induce this enzyme.
Venlafaxine is also an inhibitor of 2D6 so it modifies the
elimination of compounds metabolized by this enzyme.
Although potentially clinically significant, the degree of 2D6
inhibition with venlafaxine is less than that seen with certain
SSRIs, such as paroxetine, fluoxetine, fluvoxamine, and
sertraline (Otton et al 1996). Minor interactions have been
reported between venlafaxine and lithium, diazepam,
haloperidol, and bupropion (Troy et al 1996; Benazzi 1997;
Mekler and Woggon 1997; Kudo and Ishizaki 1999;
Kennedy et al 2002). Cimetidine should be co-administered
with caution in patients with compromised hepatic metabolic
function (Troy et al 1998). Venlafaxine should be used
cautiously in patients receiving indinavir to avoid significant
decreases in indinavir serum levels (Levin et al 2001). As is
the case with most antidepressant drugs, a potential
interaction with monoamine oxidase inhibitors (MAOIs)
exists and serious adverse reactions have been reported
(Brubacher et al 1996; Gitlin 1997; Hodgman et al 1997).The
combination of a SSRI, clomipramine or venlafaxine XR
and a MAOI poses a significant risk for life-threatening
serotonin syndrome.
Antidepressant discontinuation
syndrome
As with TCAs, MAOIs, and SSRIs, discontinuation
symptoms have been reported with venlafaxine XR (Pinzani
et al 2000; Haddad 2001; Haddad et al 2001; Reeves et al
2003; Nissen et al 2005). In addition to the common
discontinuation symptoms including dizziness, electric
shock-like sensations, anxiety, agitation, dysphoria, weeping
for no reason, and flu-like symptoms, other rare symptoms
have been described, including narcolepsy-cataplexyTherapeutics and Clinical Risk Management 2007:3(1) 67
Venlafaxine XR in panic disorder
syndrome, and neurologic symptoms mimicking stroke.
Onset of discontinuation symptoms can be associated with
stopping the antidepressant, reducing the dosage or taking
the venlafaxine XR later in the day than usual. Clinicians
should be aware of these discontinuation syndromes, since
misdiagnosis may result in inappropriate diagnostic tests
and treatment, as well as unnecessary patient morbidity
(Haddad et al 2001). Most reactions are mild. More severe
cases should be treated symptomatically or the
antidepressant can be reinstated. Discontinuation symptoms
have not been well studied and most recommendations are
based on anecdotal data or expert opinion (Haddad 2001;
Schatzberg et al 2006). However, strategies include gradual
discontinuation of antidepressant therapy, clinical
monitoring, and patient education (Schatzberg et al 2006).
Anecdotally, the author has found the central α-2 agonist,
clonidine, in low doses (0.05 mg twice daily), helpful for
some of the more disturbing symptoms (dizziness, electric
shock-like sensations) suggesting a possible noradrenergic
rebound mechanism contributing to the constellation of
discontinuation symptoms.
Summary and clinical perspective
Venlafaxine XR is effective and well tolerated in both the
short- and long-term treatment of panic disorder. Achieving
a panic-free state is a challenging treatment goal, but
venlafaxine XR has been shown to produce significantly
higher response and remission rates than placebo, and was
as effective as paroxetine in comparative trials. In the one
comparative trial, the venlafaxine XR 225 mg group had a
significantly higher percentage of panic-free patients and a
greater PDSS score improvement at endpoint than
paroxetine (Pollack et al 2005). Importantly, venlafaxine
XR significantly improved patient quality of life and
functioning, and was generally well tolerated. Encouraging
patients to face their fears in exposure-based CBT is also
an important aspect of treatment.
Since patients with panic disorder are often sensitive to
side effects (agitation, jitteriness, increased anxiety, and
panic attacks) early in the treatment with antidepressants,
the starting dose of venlafaxine XR should be low (37.5 mg
per day) for at least the first week. Once tolerated at 37.5 mg
per day, the dose may then be increased to 75 mg per day
for 2 weeks before increasing again to 150 mg. If there is
no appreciable benefit at 150 mg after 4–6 weeks, the dose
may then be increased to 225 mg per day for 4–6 weeks
before considering further increases to doses as high as
375 mg per day, if required. Clinical trials did not evaluate
doses beyond 225 mg per day, so doses above 225 mg, while
often required in clinical practice to treat “real world”
patients with co-morbid depression and other anxiety
disorders, are considered off-label. Although fixed-dose
clinical trials did not show a statistically significant treatment
effect difference between 75 mg and 225 mg per day, there
was a numerical trend suggesting possible superiority of
higher doses, which is often seen in clinical practice.
Three flexible dose trials (Liebowitz et al 2004;
Bradwejn et al 2005; Ferguson et al 2005) had mean daily
doses between 115–194.1 mg per day. Depending on the
outcome measure, therapeutic benefits including response
and sustained remission, in clinical trials, usually separated
from placebo at 4–6 weeks. There was further accrual of
therapeutic benefit in a greater number of study subjects
when treating beyond 6 weeks (eg, in the Pollack et al 2005
trial, the percentage of remitters increased from
approximately 18% at 6 weeks to approximately 50% at 12
weeks). This underscores the need in clinical practice to be
patient while awaiting the onset of therapeutic effect in panic
patients. When compared with treating major depression
without comorbidity, one should start at lower doses of
antidepressants (eg, 37.5 mg venlafaxine XR), generally
proceed to higher minimum target doses (eg, 150–225 mg
venlafaxine XR) and wait longer for onset of therapeutic
benefit (sometimes 8–12 weeks) when treating panic
disorder.
There is little empirical evidence to guide clinicians
regarding the length of treatment with antidepressants for
panic disorder. General consensus among experts in the
treatment of anxiety disorders is that anxiety disorder
treatment should be longer than that recommended for an
index episode of depression. The author usually treats for 2
years after panic attacks have ceased, at the dose required
to stop the panic attacks. Adequate time is necessary for
exposure through behavioral therapy to minimize or
eradicate agoraphobic avoidance. The antidepressant would
then be tapered slowly over a period of 6 months while
observing for any signs of recurrence.
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